Form 4: EyePoint Pharmaceuticals Director Anthony P. Adamis Reports Stock Transactions

Director Anthony P. Adamis of EyePoint Pharmaceuticals reports the acquisition and disposal of common stock and restricted stock units on June 23, 2024.

Summary

• On June 23, 2024, Anthony P. Adamis, a director at EyePoint Pharmaceuticals, engaged in transactions involving the company's stock.
• Adamis acquired 2,000 shares of common stock at $0.00.
• Simultaneously, Adamis disposed of 2,000 shares of common stock.
• The transactions also involved restricted stock units, with 2,000 units converted into common stock.
• Following these transactions, Adamis directly owns 2,000 derivative securities.
• The restricted stock units vest in three ratable annual installments beginning June 23, 2023.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director, indicating neutral sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect a broader trend in the pharmaceutical industry but rather individual investment decisions.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates